Nuvalent Raises $300M in Public Stock Offering
TL;DR Summary
Cancer biotech company Nuvalent has announced a $300 million public offering of its common stock following positive Phase I results for its ALK-selective tyrosine kinase inhibitor candidate, NVL-655, in ALK-positive non-small cell lung cancer patients, with a 39% objective response rate observed in evaluable patients.
Topics:business#alk-selective-tyrosine-kinase-inhibitor#biotechpharmaceuticals#cancer-biotech#non-small-cell-lung-cancer#nuvalent#public-offering
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
0 min
vs 1 min read
Condensed
58%
107 → 45 words
Want the full story? Read the original article
Read on Endpoints News